Psychiatr. pro Praxi, 2002; 4: 152-157

Rizika polyfarmakoterapie

prof. MUDr. Eva Hadašová CSc
Farmakologický ústav lékařské fakulty Masarykovy univerzity, Brno

Keywords: polypharmacotherapy, psychotropic drugs, drug interactions, pharmacokinetics, pharmacodynamics.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hadašová E. Rizika polyfarmakoterapie. Psychiatr. praxi. 2002;3(4):152-157.

Článek podává základní informaci o farmakologickém riziku polyfarmakoterapie v psychiatrii. Jsou diskutovány výhody a nevýhody, které může přinášet kombinační léčba v psychiatrii a popsány možné mechanizmy interakcí na farmakokinetické a farmakodynamické úrovni.

PITFALLS OF POLYPHARMACOTHERAPY

The present paper supplies basic information about the pharmacological risks of polypharmacotherapy in psychiatry. The positive features and the drawbacks of combined therapy are discussed and the possible mechanisms of drug interactions on the pharmacokinetic and pharmacodynamic levels are described.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ament PW, Bertolino JG, Liszewski JL. Clinically important drug interactions. Am Fam Physician 2000; 61: 1745-1754. Go to PubMed...
    2. Bertilsson L, Dahl M-L, Sjokvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993; 341: 63-66. Go to original source... Go to PubMed...
    3. Doraiswamy P. Contemporary management of comorbid anxiety and depression in geriatric patients. J Clin Psychiatry 2001; 62: 30-35.
    4. Fava M. Augmentation and combination strategies in treatment-resistent depression. J clin Psychiatry 2001; Suppl 18/62: 4-11.
    5. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000; 61: 9-15. Go to original source... Go to PubMed...
    6. Goff DC, Baldessarini RJ. Drug interactions with antipsychotic agents. J Clin Psychopharmacol 1993; 13: 57-67. Go to original source... Go to PubMed...
    7. Gomez Gomez JM, Perramon CT. Combined treatment with venlafaxine and tricyclic antidepressants in depressed patients who had partial response to clomipramine or imipramine: Initial findings. J Clin Psychiatry 2000; 61: 285-289.
    8. Hadašová E. Genetický polymorfismus metabolismu psychotropních látek a jeho klinické důsledky. ČS Psychiat 1995; 91: 352-360. Go to original source...
    9. Hadašová E. Acetylační polymorfismus a jeho klinické důsledky. Klin. farmakol. farmac. 2002; 16: v tisku.
    10. Janicak PG. Handbook of psychopharmacotherapy. Lippincott Williams & Wilkins, Baltimore 1999; 391 s.
    11. Kane GC, Lipsky JJ. Drug-grapefruit juice interactions. Mayo Clin Proc 2000; 75: 933-942. Go to original source... Go to PubMed...
    12. Kriška M. Riziko liekov v medicínskej praxi. Slovak Academic Press, Bratislava 2000; 474 s.
    13. Leonard BE. Fundamentals of psychopharmacology. John Wiley & Sons, Chichester 1997; 394 s.
    14. Levitt AJ, Joffe RT, Kamil R, McIntyre R. Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination? J Clin Psychiatry 1999; 60: 613-616. Go to original source... Go to PubMed...
    15. Livingston MG, Livingston HM. Monoamine oxidase inhibitors. An update on drug interactions. Drug safety 1996; 14: 219-227. Go to original source... Go to PubMed...
    16. Quinn DJ, Day RO. Clinically important drug interactions. In: Speigt TM, Holford NHG (eds.). Avery´s drug treatment. Adis International, Auckland 1997; 301-338.
    17. Švestka J, et al. Psychofarmaka v klinické praxi. Grada Publishing, Praha 1995; 252 s.
    18. Woolston JL. Combined pharmacotherapy: pitfalls of treatment. J Amer Acad Child Adolesc Psychiatry 1999; 38: 1455-1457. Go to original source... Go to PubMed...
    19. Zelenková O, Hadašová E, Češková E, et al. Effects of psychopharmacotherapy on phenotypic expression of cytochrome P450 2D6 in patients genotyped for CYP2D6 mutations. Human Psychopharmacol 2000; 4: 303-305. Go to original source...
    20. Žourková A, Hadašová E, Vávrová M, et al. Vedlejší účinky léčby paroxetinem v závislosti na aktivitě CYP 2D6. Psychiatrie 2001; Suppl 2/6: 149-151.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.